110962 ⎘
ssRNA viruses negative-sense; Details; Paramyxoviridae; Morbillivirus, e.g. Measles virus, canine distemper Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
BETACORONAVIRUS mRNA VACCINES
#2BETACORONAVIRUS mRNA VACCINES
#3HUMAN CTLA-4 PEPTIDE VACCINES AND USES THEREOF
#4SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES
#5BETACORONA VIRUS mRNA VACCINES
#6BETACORONAVIRUS mRNA VACCINES
#7MULTIVALENT VIRAL PARTICLES
#8COMBINATION HMPV/RSV RNA VACCINES
#9Betacoronavirus RNA vaccines
#10COMBINATION HMPV/RSV RNA VACCINES
#11Methods and Materials for Using Measles Viruses
#12COMBINATION HMPV/RSV RNA VACCINES
#13METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND VACCINES THEREOF
#14Methods of vaccine administration
#15MEASLES VIRUS ENCODING A TUMOR ANTIGEN
#16Triple live vaccine of canine distemper virus, canine parvovirus and canine infectious hepatitis virus
#17Modified viruses
#18Methods and materials for using measles viruses
#19Measles virus vaccine expressing SARS-CoV-2 protein(s)
#20COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES
#21System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
#22Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#23Oral dissolving films containing microencapsulated vaccines and methods of making same
#24Combination HMPV/RSV RNA vaccines
#25Liquid vaccines of live enveloped viruses
#26Aseptic purification process for viruses
#27Methods of vaccine administration
#28Methods and materials for detecting SNPs and administering measles virus
#29Lassa vaccine
#30Betacoronavirus mRNA vaccine
#31Paramyxoviridae expression system
#32Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
#33Betacoronavirus mRNA vaccine
#34Modified viruses
#35Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#36Intranasal vector vaccine against porcine epidemic diarrhea
#37Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
#38Method for producing self-assembling paramyxoviral nucleocapsid-like particles and their uses
#39HPIV3 RNA vaccines
#40hMPV RNA vaccines
#41Tobacco products
#42PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
#43Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
#44Recombinant Zika vaccines
#45Method and apparatus for microneedle transdermal delivery
#46Biomembrane, closed structure with biomembrane characteristics or cellular compartment derived from natural sources and/or self-assembly techniques, preparation method and applications thereof
#47Chromatography based purification strategies for viruses
#48METHOD TO PRODUCE A MEDICINAL PRODUCT COMPRISING A BIOLOGICALLY ACTIVE PROTEIN AND THE RESULTING PRODUCT
#49Compositions and methods for stabilization of active agents
#50Manufacture of vaccines and compositions for the prevention of infections
#51Methods for the prevention of infections
#52Tunable vaccine platform against pathogens of the paramyxovirus family
#53Combination PIV3/hMPV RNA vaccines
#54Methods and materials for detecting SNPS and administering measles virus vaccinations
#55Oral dissolving films
#56Universal cancer vaccine
#57PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
#58Methods and compositions for therapeutic agents
#59Live recombinant measles-M2 virus—its use in eliciting immunity against influenza viruses
#60Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
#61Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
#62Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#63Methods and products for treating and/or delaying onset of dysplastic lesions
#64DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES
#65Aseptic purification process for viruses
#66Measles virus encoding a tumor antigen
#67Gene-modified measles virus for tumor treatment use
#68VIRUS VECTOR, CELL, AND CONSTRUCT
#69Antigen delivery system
#70COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS
#71Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
#72Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
#73Nanospheres encapsulating bioactive material and method for formulation of nanospheres
#74Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
#75Method of making a virus using duck embryonic derived stem cell lines
#76Nasal mucosal vaccine composition
#77Dry formulations of vaccines that are room temperature stable
#78Thermally stable vaccine formulations and microneedles
#79Bacterial vaccine and methods for manufacture thereof
#80Neutralization-resistant CDV mutants and viral vectors
#81Recombinant CDV compositions and uses thereof
#82Mucosal vaccine composition
#83Methods of immunization with varicella zoster virus antigen
#84PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE
#85Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#86Single high dose of MVA induces a protective immune response in neonates and infants
#87Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
#88Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
#89VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA
#90Liquid stable virus vaccines
#91Recombinant measles virus expressing chikungunya virus polypeptides and their applications
#92Reverse genetics of negative-strand RNA viruses in yeast
#93Medicaments and methods for treating mesothelioma
#94Methods of vaccine administration
#95METHOD TO PRODUCE A MEDICINAL PRODUCT COMPRISING A BIOLOGICALLY ACTIVE PROTEIN AND THE RESULTING PRODUCT
#96METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
#97Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection
#98Combined measles-malaria vaccine
#99Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
#100Viruses lacking epithelial cell receptor entry
#101Immunization compositions and methods
#102Liquid stable virus vaccines
#103Vaccine injection, preparation method and use thereof
#104Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
#105Feline morbillivirus and uses thereof
#106Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
#107Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#108Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Malarial Infections
#109Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Nipah Infections
#110Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
#111Combined measles-malaria vaccine
#112METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS
#113PARAPOXVIRUS VECTORS
#114CDNA corresponding to the antigenome of nonsegmented negative strand RNA viruses, and process for the production of such viruses encoding additional antigenically active proteins
#115Reverse genetics of negative-strand RNA viruses in yeast
#116Settings for recombinant adenoviral-based vaccines
#117Recombinant CDV compositions and uses thereof
#118Immunization compositions and methods
#119Stabilisation of Viral Microparticles
#120Settings for recombinant adenoviral-based vaccines
#121Combined measles-human papilloma vaccine
#122NOVEL VACCINE FOR DOG
#123Formulation for room temperature stabilization of a live attenuated bacterial vaccine
#124RECOMBINANT MODIFIED VACCINIA VIRUS MEASLES VACCINE
#125Viruses lacking epithelial cell receptor entry
#126ANTI-MEASLES CANCER IMMUNOTHERAPY
#127Medicaments and methods for treating mesothelioma
#128Stabilizers for freeze-dried vaccines
#129Immunogenic Compositions and Methods for Treating and Preventing Animal Infections
#130Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection
#131DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES
#132METHODS OF VACCINE ADMINISTRATION
#133Settings for recombinant adenoviral-based vaccines
#134MEASLES SUBUNIT VACCINE
#135Raccoon poxvirus expressing rabies glycoproteins
#136METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS
#137Vaccine For Periodontal Disease
#138Canine combination vaccines
#139CANINE VACCINES
#140Settings for recombinant adenoviral-based vaccines
#141cDNA corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses
#142Attenuated parainfluenza virus (PIV) vaccines
#143Vaccines
#144Infectious recombinant paramyxovirus from antigenomic cDNA
#145Stabilisation of viral microparticles
#146DNA expression vectors and methods of use
#147Recombinant measles viruses expressing epitopes of antigens of RNA viruses - use for the preparation of vaccine compositions
#148Recombinant therapeutic fusion proteins
#149Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
#150Settings for recombinant adenoviral-based vaccines
#151Measles subunit vaccine
#152Coronavirus-like particles comprising functionally deleted genomes
#153Canine vaccines against Bordetella bronchiseptica
#154Microencapsulated DNA for vaccination and gene therapy
#155Vaccine for periodontal disease
#156Transient expression of biologic materials
#157Oral vaccine for peste-des-petits-ruminants virus